ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Dextrose and sodium chloride: Pediatric drug information

Dextrose and sodium chloride: Pediatric drug information
(For additional information see "Dextrose and sodium chloride: Drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Therapeutic Category
  • Intravenous Nutritional Therapy
Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified. Also see Dextrose and Sodium Chloride monographs.

Postmarketing:

Dermatologic: Injection site blister formation, pruritus, skin rash

Endocrine & metabolic: Hyperchloremic metabolic acidosis, hyperglycemia, hypernatremia, hypervolemia, hyponatremia

Hypersensitivity: Anaphylaxis, hypersensitivity reaction

Local: Injection site phlebitis, pain at injection site, venous thrombosis at injection site

Nervous system: Chills, encephalopathy (hyponatremic)

Miscellaneous: Febrile reaction, fever

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: Dextrose 10% and sodium chloride 0.2% (250 mL); Dextrose 10% and sodium chloride 0.45% (1000 mL); Dextrose 2.5% and sodium chloride 0.45% (1000 mL); Dextrose 5% and sodium chloride 0.2% (250 mL, 500 mL, 1000 mL); Dextrose 5% and sodium chloride 0.33% (500 mL); Dextrose 5% and sodium chloride 0.45% (500 mL, 1000 mL); Dextrose 5% and sodium chloride 0.9% (500 mL, 1000 mL)

Solution, Intravenous [preservative free]:

Generic: Dextrose 2.5% and sodium chloride 0.45% (1000 mL); Dextrose 5% and sodium chloride 0.2% (250 mL, 500 mL, 1000 mL); Dextrose 5% and sodium chloride 0.3% (250 mL, 500 mL, 1000 mL); Dextrose 5% and sodium chloride 0.45% (250 mL, 500 mL, 1000 mL); Dextrose 5% and sodium chloride 0.9% (500 mL, 1000 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Dextrose-Sodium Chloride Intravenous)

2.5-0.45% (per mL): $0.01

5-0.225% (per mL): $0.01

5-0.3% (per mL): $0.01

5-0.45% (per mL): $0.01

5-0.9% (per mL): $0.01

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: 10-0.9 % (1000 mL); 3.3-0.3 % (50 mL, 100 mL, 250 mL, 500 mL, 1000 mL); Dextrose 5% and sodium chloride 0.2% (250 mL, 500 mL, 1000 mL); Dextrose 5% and sodium chloride 0.45% (500 mL, 1000 mL); Dextrose 5% and sodium chloride 0.9% (250 mL, 500 mL, 1000 mL)

Use

Source of calories, sodium chloride, and water for hydration

Medication Safety Issues
Other safety concerns:

Inappropriate use of low sodium or sodium-free intravenous fluids (eg D5W, hypotonic saline) in pediatric patients can lead to significant morbidity and mortality due to hyponatremia (ISMP 2009)

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Lithium: Sodium Chloride may increase the excretion of Lithium. Risk C: Monitor therapy

Tolvaptan: Sodium Chloride may enhance the adverse/toxic effect of Tolvaptan. Specifically, Hypertonic Saline may increase the risk for too rapid of an increase in serum sodium concentrations. Management: This interaction is specific to hypertonic saline. Avoid concurrent use of hypertonic saline with tolvaptan. Risk X: Avoid combination

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (QA) Qatar: Norsalin-D
  1. Dextrose 2.5% and sodium chloride 0.45% injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; November 2019.
  2. Institute for Safe Medication Practice, “Plain D5W or Hypotonic Saline Solutions Post-Op Could Result in Acute Hyponatremia and Death in Healthy Children,” ISMP Medication Safety Alert, August 13, 2009. Available at http://www.ismp.org/Newsletters/acutecare/articles/20090813.asp
Topic 108436 Version 114.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟